AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 214 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $6,124,000 | +3.1% | 118,586 | -13.5% | 0.01% | 0.0% |
| Q4 2020 | $5,938,000 | +31.9% | 137,033 | +6.6% | 0.01% | +25.0% |
| Q3 2020 | $4,501,000 | -32.7% | 128,600 | +2.9% | 0.00% | -42.9% |
| Q2 2020 | $6,685,000 | +53.0% | 125,000 | +1.5% | 0.01% | +40.0% |
| Q1 2020 | $4,368,000 | -23.3% | 123,100 | +3.2% | 0.01% | 0.0% |
| Q4 2019 | $5,697,000 | +103.5% | 119,307 | +38.1% | 0.01% | +66.7% |
| Q3 2019 | $2,799,000 | -8.5% | 86,400 | +40.9% | 0.00% | -25.0% |
| Q2 2019 | $3,058,000 | -27.1% | 61,300 | -1.4% | 0.00% | -20.0% |
| Q1 2019 | $4,195,000 | +44.0% | 62,200 | -1.6% | 0.01% | +25.0% |
| Q4 2018 | $2,914,000 | -51.8% | 63,200 | -19.4% | 0.00% | -50.0% |
| Q3 2018 | $6,048,000 | -13.3% | 78,417 | -5.4% | 0.01% | -20.0% |
| Q2 2018 | $6,979,000 | +9.4% | 82,859 | +6.2% | 0.01% | +11.1% |
| Q1 2018 | $6,379,000 | +36.4% | 78,000 | -4.6% | 0.01% | +50.0% |
| Q4 2017 | $4,677,000 | +94.1% | 81,800 | +126.6% | 0.01% | +50.0% |
| Q3 2017 | $2,410,000 | +34.2% | 36,100 | +3.4% | 0.00% | +33.3% |
| Q2 2017 | $1,796,000 | -9.8% | 34,900 | +2.3% | 0.00% | 0.0% |
| Q1 2017 | $1,991,000 | +34.0% | 34,100 | -4.2% | 0.00% | +50.0% |
| Q4 2016 | $1,486,000 | -24.8% | 35,600 | -4.8% | 0.00% | -33.3% |
| Q3 2016 | $1,976,000 | +17.6% | 37,400 | -6.7% | 0.00% | 0.0% |
| Q2 2016 | $1,680,000 | -0.1% | 40,100 | -3.1% | 0.00% | 0.0% |
| Q1 2016 | $1,681,000 | -41.0% | 41,400 | -5.7% | 0.00% | -40.0% |
| Q4 2015 | $2,850,000 | -18.3% | 43,900 | -11.1% | 0.01% | -16.7% |
| Q3 2015 | $3,487,000 | -36.5% | 49,400 | 0.0% | 0.01% | -25.0% |
| Q2 2015 | $5,490,000 | +1711.9% | 49,400 | +1958.3% | 0.01% | – |
| Q1 2015 | $303,000 | 0.0% | 2,400 | 0.0% | 0.00% | – |
| Q4 2014 | $303,000 | -90.1% | 2,400 | -96.4% | 0.00% | -100.0% |
| Q2 2014 | $3,063,000 | +12662.5% | 66,853 | +6585.3% | 0.00% | – |
| Q4 2013 | $24,000 | -14.3% | 1,000 | 0.0% | 0.00% | – |
| Q3 2013 | $28,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |